Step 1 of 12: Clinical and Research Readiness

Welcome to Step 1 of the recovery program.

No, this is not the part where you admit you have a problem. I'm trying to catch you before that happens.

Last week I told you FDA clearance is not a commercial strategy. This week I'm going to tell you your clinical data probably is not as ready for the U.S. market as you think it is.

Don't take it personally. Almost nobody's is.

We all go through it no matter how prepared we are. Let's mitigate as much risk as possible together.

The Room You're Walking Into

Picture this. You fly to the U.S. You book a meeting with a respected physician at a major academic medical center. You pull up your clinical data.

By slide three, they're mentally somewhere else entirely.

Not because your data is bad. Because it didn't answer the questions they actually cared about.

Also, you opened your laptop five minutes into dinner before building any relationship whatsoever. Which is a completely separate MedTech disease we'll diagnose later.

U.S. clinicians are busy, skeptical, politically constrained, and constantly being pitched by someone who claims they are "revolutionizing healthcare." Half of those companies disappear before the hospital finishes legal review.

What they actually want to know is:

• Workflow: Does this fit into my workflow OR create operational chaos?

• Adoption Stage: Have any of my peers used it yet, or am I about to become a beta tester with a medical license?

• Reputation: If I am a first or early adopter, how will my reputation be impacted if things don't go well with my peers or the hospital administration?

• Evidence: Does this evidence actually reflect U.S. patients and U.S. hospital reality?

• Peer Momentum: Who in this country is willing to publicly stand behind this?

And here's the important part:

A physician being interested in your technology is not the same thing as them being willing to commercially champion it.

Those are two completely different relationships. Let me say this again...

A physician being interested in your technology is not the same thing as them being willing to commercially champion it.

You don't propose on the first date.

You earn that over time through trust, results, responsiveness, and by making their life easier instead of harder.

Early meetings are where you figure out whether someone wants to:

• casually observe,

• scientifically collaborate,

• commercially advocate,

• or simply add your company logo to their "interesting things I'm involved with" collection.

Read the room correctly.

Curiosity comes first. Advocacy comes later.

Three Ways Founders Blow This

1. Confusing FDA Clearance With Clinical Validation

   FDA clearance means the FDA agreed your product is reasonably safe and effective for its intended use. That is not the same thing as a U.S. clinician believing it is worth changing behavior for. Those are wildly different standards.
   

2. Overestimating What International Data Does in the U.S.

   Your international study matters. It just doesn't automatically travel.

   Different workflows.

   Different reimbursement structures.

   Different liability concerns.

   Different hospital politics.

   Bring the data. Just don't present it like you arrived carrying the sacred scrolls from Mount Clinical Evidence. Because somewhere in the back of the room, an American surgeon is already thinking: "Cool. But what happens at my hospital?"
   

3. Picking the Wrong First Site

   This one matters more than people realize. I've made this mistake myself.

   Big-name institution. Check.

   Excited physician. Check.

   Strong energy in the room. Check.

   
   

   We pushed hard toward collaboration. What I didn't fully appreciate at the time was this:

   The clinical interest was real. The commercial intent was not.

   The physician liked being associated with something innovative.

   The institution liked talking about shiny new technology.

   Everyone enjoyed the idea of participation.

   What never happened: adoption, scale, expansion, or anything remotely resembling a commercial pathway.

The U.S. market does not punish bad technology nearly as often as it punishes bad strategy.

And site selection is strategy.

A famous logo on your slide deck means absolutely nothing if the relationship was never designed to go anywhere.

What Actually Moves the Needle

KOL Strategy Is Not a Contact List

This is where most companies accidentally build a networking spreadsheet and call it a commercialization plan. Real KOL strategy is about building relationships with people who actually influence behavior. Not just recognizable names.

You need:

• champions,

• validators,

• challengers,

• early adopters,

• peer-to-peer influencers,

• and people who will answer the phone when another physician asks,

  
  

"Have you actually used this thing?"

That matters infinitely more than another conference photo.

Breadth matters.

Depth matters more.

Breadth means: different geographies, different institution types, different practice environments.

Depth means: when something inevitably goes sideways, your network still stands behind you. Because something will go sideways.

This is MedTech. We turned printer troubleshooting into a 14-person hospital committee.

And yes, most KOLs will still require consulting agreements. Humanity remains committed to consistency.

Study Design Is a Commercial Decision

Successful science is great. Selling successful science is better.

Most MedTech studies are designed by scientists, reviewed by scientists, and published for scientists.

Which is important...and also completely insufficient commercially.

Someone with commercial instincts needs to be involved while the study is being designed.

Not to compromise the science but to make sure the study captures what the market actually needs to see.

Because here's what happens constantly. A company finishes a study and realizes six months later they never tracked:

• procedure time,

• staffing impact,

• workflow disruption,

• room turnover,

• reimbursement implications,

• supply utilization,

• patient friction,

• operational burden.

The list goes on...Which is unfortunate because those are exactly the things hospital leadership cares about.

A surgeon may love your outcomes.

The CFO still wants to know why the case now takes 47 extra minutes and requires three additional staff members named Chad.

If you don't collect operational and economic data early, you usually never get another clean chance to collect it later.

That information disappears forever.

Before your study starts, ask:

• What does the CFO need to see?

• What does the payer need to justify reimbursement?

• What does the Value Analysis Committee need to feel comfortable?

• What does the skeptical department chair need in order to stop resisting this?

If your study design doesn't at least move toward those answers, you're probably creating future problems for yourself. Expensive ones.

The Short Version

• Map the U.S. clinical landscape before you enter it

• Build real KOL relationships, not just a contact database

• Define your early adopter profile before selecting sites

• Put commercial thinking into study design early

• Collect operational and economic data during studies

• Build clinical relationships before asking people for favors

• Create a post-clearance publication and evidence roadmap now

None of this is incredibly complicated.

It's just easy to ignore when everyone is celebrating FDA clearance like the journey is over.

The journey is not over. You just reached the part where the hospital starts involving committees.

Bottom Line

Clinical readiness is not just about having data.

It's about having the right data, collected the right way, with the right partners, answering the right commercial and clinical questions.

Successful science creates credibility. Commercially useful science creates revenue. You need both.

And the best time to think about commercialization is before the first study starts, not halfway through a pilot when the VAC asks for numbers nobody collected.

I'd rather help someone build this correctly upfront than untangle it halfway through a stalled pilot.

One of those conversations is significantly more enjoyable for everyone involved.

Next week:

Step 2 of 12: Regulatory, Quality, and Risk Architecture

The part where you discover that FDA clearance and hospital compliance are very different things... and hospital IT departments have surprisingly strong opinions about both.

👉 Take the U.S. Commercial Readiness Self-Assessment to see how prepared you are.